ID   POLH_HUMAN              Reviewed;         713 AA.
AC   Q9Y253; Q7L8E3; Q96BC4; Q9BX13;
DT   15-FEB-2005, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1999, sequence version 1.
DT   22-JUL-2015, entry version 134.
DE   RecName: Full=DNA polymerase eta;
DE            EC=2.7.7.7;
DE   AltName: Full=RAD30 homolog A;
DE   AltName: Full=Xeroderma pigmentosum variant type protein;
GN   Name=POLH; Synonyms=RAD30, RAD30A, XPV;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), PROTEIN SEQUENCE OF 132-163;
RP   395-404; 429-450 AND 495-511, FUNCTION, INVOLVEMENT IN XPV, AND
RP   ALTERNATIVE SPLICING.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=10385124; DOI=10.1038/21447;
RA   Masutani C., Kusumoto R., Yamada A., Dohmae N., Yokoi M., Yuasa M.,
RA   Araki M., Iwai S., Takio K., Hanaoka F.;
RT   "The XPV (Xeroderma pigmentosum variant) gene encodes human DNA
RT   polymerase eta.";
RL   Nature 399:700-704(1999).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT XPV LEU-75 DEL.
RX   PubMed=10398605; DOI=10.1126/science.285.5425.263;
RA   Johnson R.E., Kondratick C.M., Prakash S., Prakash L.;
RT   "hRAD30 mutations in the variant form of xeroderma pigmentosum.";
RL   Science 285:263-265(1999).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND INVOLVEMENT IN XPV.
RX   PubMed=11032022; DOI=10.1038/sj.onc.1203842;
RA   Yuasa M., Masutani C., Eki T., Hanaoka F.;
RT   "Genomic structure, chromosomal localization and identification of
RT   mutations in the xeroderma pigmentosum variant (XPV) gene.";
RL   Oncogene 19:4721-4728(2000).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS VAL-209; TRP-334;
RP   MET-478; PRO-584; VAL-595 AND LEU-647.
RG   NIEHS SNPs program;
RL   Submitted (SEP-2003) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=14574404; DOI=10.1038/nature02055;
RA   Mungall A.J., Palmer S.A., Sims S.K., Edwards C.A., Ashurst J.L.,
RA   Wilming L., Jones M.C., Horton R., Hunt S.E., Scott C.E.,
RA   Gilbert J.G.R., Clamp M.E., Bethel G., Milne S., Ainscough R.,
RA   Almeida J.P., Ambrose K.D., Andrews T.D., Ashwell R.I.S.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Banerjee R., Barker D.J.,
RA   Barlow K.F., Bates K., Beare D.M., Beasley H., Beasley O., Bird C.P.,
RA   Blakey S.E., Bray-Allen S., Brook J., Brown A.J., Brown J.Y.,
RA   Burford D.C., Burrill W., Burton J., Carder C., Carter N.P.,
RA   Chapman J.C., Clark S.Y., Clark G., Clee C.M., Clegg S., Cobley V.,
RA   Collier R.E., Collins J.E., Colman L.K., Corby N.R., Coville G.J.,
RA   Culley K.M., Dhami P., Davies J., Dunn M., Earthrowl M.E.,
RA   Ellington A.E., Evans K.A., Faulkner L., Francis M.D., Frankish A.,
RA   Frankland J., French L., Garner P., Garnett J., Ghori M.J.,
RA   Gilby L.M., Gillson C.J., Glithero R.J., Grafham D.V., Grant M.,
RA   Gribble S., Griffiths C., Griffiths M.N.D., Hall R., Halls K.S.,
RA   Hammond S., Harley J.L., Hart E.A., Heath P.D., Heathcott R.,
RA   Holmes S.J., Howden P.J., Howe K.L., Howell G.R., Huckle E.,
RA   Humphray S.J., Humphries M.D., Hunt A.R., Johnson C.M., Joy A.A.,
RA   Kay M., Keenan S.J., Kimberley A.M., King A., Laird G.K., Langford C.,
RA   Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C.R., Lloyd D.M.,
RA   Loveland J.E., Lovell J., Martin S., Mashreghi-Mohammadi M.,
RA   Maslen G.L., Matthews L., McCann O.T., McLaren S.J., McLay K.,
RA   McMurray A., Moore M.J.F., Mullikin J.C., Niblett D., Nickerson T.,
RA   Novik K.L., Oliver K., Overton-Larty E.K., Parker A., Patel R.,
RA   Pearce A.V., Peck A.I., Phillimore B.J.C.T., Phillips S., Plumb R.W.,
RA   Porter K.M., Ramsey Y., Ranby S.A., Rice C.M., Ross M.T., Searle S.M.,
RA   Sehra H.K., Sheridan E., Skuce C.D., Smith S., Smith M., Spraggon L.,
RA   Squares S.L., Steward C.A., Sycamore N., Tamlyn-Hall G., Tester J.,
RA   Theaker A.J., Thomas D.W., Thorpe A., Tracey A., Tromans A., Tubby B.,
RA   Wall M., Wallis J.M., West A.P., White S.S., Whitehead S.L.,
RA   Whittaker H., Wild A., Willey D.J., Wilmer T.E., Wood J.M., Wray P.W.,
RA   Wyatt J.C., Young L., Younger R.M., Bentley D.R., Coulson A.,
RA   Durbin R.M., Hubbard T., Sulston J.E., Dunham I., Rogers J., Beck S.;
RT   "The DNA sequence and analysis of human chromosome 6.";
RL   Nature 425:805-811(2003).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Skin;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   FUNCTION, AND MUTAGENESIS.
RX   PubMed=11743006; DOI=10.1093/emboj/20.24.7303;
RA   Glick E., Vigna K.L., Loeb L.A.;
RT   "Mutations in human DNA polymerase eta motif II alter bypass of DNA
RT   lesions.";
RL   EMBO J. 20:7303-7312(2001).
RN   [8]
RP   FUNCTION.
RX   PubMed=11376341; DOI=10.1038/88740;
RA   Zeng X., Winter D.B., Kasmer C., Kraemer K.H., Lehmann A.R.,
RA   Gearhart P.J.;
RT   "DNA polymerase eta is an A-T mutator in somatic hypermutation of
RT   immunoglobulin variable genes.";
RL   Nat. Immunol. 2:537-541(2001).
RN   [9]
RP   SUBCELLULAR LOCATION, AND INTERACTION WITH POLI.
RX   PubMed=12606586; DOI=10.1093/emboj/7595006;
RA   Kannouche P.L., Fernandez de Henestrosa A.R., Coull B., Vidal A.E.,
RA   Gray C., Zicha D., Woodgate R., Lehmann A.R.;
RT   "Localization of DNA polymerases eta and iota to the replication
RT   machinery is tightly co-ordinated in human cells.";
RL   EMBO J. 22:1223-1233(2003).
RN   [10]
RP   FUNCTION, AND SCHIFF BASE FORMATION.
RX   PubMed=14630940; DOI=10.1101/gad.1146103;
RA   Haracska L., Prakash L., Prakash S.;
RT   "A mechanism for the exclusion of low-fidelity human Y-family DNA
RT   polymerases from base excision repair.";
RL   Genes Dev. 17:2777-2785(2003).
RN   [11]
RP   MUTAGENESIS OF TYR-52.
RX   PubMed=12644469; DOI=10.1074/jbc.M300686200;
RA   Glick E., Chau J.S., Vigna K.L., McCulloch S.D., Adman E.T.,
RA   Kunkel T.A., Loeb L.A.;
RT   "Amino acid substitutions at conserved tyrosine 52 alter fidelity and
RT   bypass efficiency of human DNA polymerase eta.";
RL   J. Biol. Chem. 278:19341-19346(2003).
RN   [12]
RP   FUNCTION.
RX   PubMed=14734526; DOI=10.1084/jem.20031831;
RA   Faili A., Aoufouchi S., Weller S., Vuillier F., Stary A., Sarasin A.,
RA   Reynaud C.-A., Weill J.-C.;
RT   "DNA polymerase eta is involved in hypermutation occurring during
RT   immunoglobulin class switch recombination.";
RL   J. Exp. Med. 199:265-270(2004).
RN   [13]
RP   INTERACTION WITH MONOUBIQUITINATED PCNA.
RX   PubMed=15149598; DOI=10.1016/S1097-2765(04)00259-X;
RA   Kannouche P.L., Wing J., Lehmann A.R.;
RT   "Interaction of human DNA polymerase eta with monoubiquitinated PCNA:
RT   a possible mechanism for the polymerase switch in response to DNA
RT   damage.";
RL   Mol. Cell 14:491-500(2004).
RN   [14]
RP   UBIQUITINATION AT LYS-682; LYS-686; LYS-694 AND LYS-709.
RX   PubMed=20159558; DOI=10.1016/j.molcel.2009.12.039;
RA   Bienko M., Green C.M., Sabbioneda S., Crosetto N., Matic I.,
RA   Hibbert R.G., Begovic T., Niimi A., Mann M., Lehmann A.R., Dikic I.;
RT   "Regulation of translesion synthesis DNA polymerase eta by
RT   monoubiquitination.";
RL   Mol. Cell 37:396-407(2010).
RN   [15]
RP   UBIQUITINATION BY RCHY1/PIRH2.
RX   PubMed=21791603; DOI=10.1128/MCB.05808-11;
RA   Jung Y.S., Hakem A., Hakem R., Chen X.;
RT   "Pirh2 E3 ubiquitin ligase monoubiquitinates DNA polymerase eta to
RT   suppress translesion DNA synthesis.";
RL   Mol. Cell. Biol. 31:3997-4006(2011).
RN   [16]
RP   INTERACTION WITH PALB2 AND BRCA2.
RX   PubMed=24485656; DOI=10.1016/j.celrep.2014.01.009;
RA   Buisson R., Niraj J., Pauty J., Maity R., Zhao W., Coulombe Y.,
RA   Sung P., Masson J.Y.;
RT   "Breast cancer proteins PALB2 and BRCA2 stimulate polymerase eta in
RT   recombination-associated DNA synthesis at blocked replication forks.";
RL   Cell Rep. 6:553-564(2014).
RN   [17]
RP   VARIANTS XPV GLU-535 AND THR-589.
RX   PubMed=11121129; DOI=10.1046/j.1523-1747.2000.00154.x;
RA   Itoh T., Linn S., Kamide R., Tokushige H., Katori N., Hosaka Y.,
RA   Yamaizumi M.;
RT   "Xeroderma pigmentosum variant heterozygotes show reduced levels of
RT   recovery of replicative DNA synthesis in the presence of caffeine
RT   after ultraviolet irradiation.";
RL   J. Invest. Dermatol. 115:981-985(2000).
RN   [18]
RP   VARIANTS XPV LEU-75 DEL; HIS-111 PRO-122; VAL-263 AND SER-361.
RX   PubMed=11773631; DOI=10.1073/pnas.022473899;
RA   Broughton B.C., Cordonnier A., Kleijer W.J., Jaspers N.G., Fawcett H.,
RA   Raams A., Garritsen V.H., Stary A., Avril M.-F., Boudsocq F.,
RA   Masutani C., Hanaoka F., Fuchs R.P.P., Sarasin A., Lehmann A.R.;
RT   "Molecular analysis of mutations in DNA polymerase eta in xeroderma
RT   pigmentosum variant patients.";
RL   Proc. Natl. Acad. Sci. U.S.A. 99:815-820(2002).
RN   [19]
RP   VARIANTS XPV VAL-37 DEL; PRO-93; ASP-266; ARG-295 AND ALA-692.
RX   PubMed=24130121; DOI=10.1002/humu.22462;
RA   Opletalova K., Bourillon A., Yang W., Pouvelle C., Armier J.,
RA   Despras E., Ludovic M., Mateus C., Robert C., Kannouche P., Soufir N.,
RA   Sarasin A.;
RT   "Correlation of phenotype/genotype in a cohort of 23 xeroderma
RT   pigmentosum-variant patients reveals 12 new disease-causing POLH
RT   mutations.";
RL   Hum. Mutat. 35:117-128(2014).
RN   [20]
RP   VARIANT [LARGE SCALE ANALYSIS] ASP-153.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S.,
RA   Buckhaults P., Farrell C., Meeh P., Markowitz S.D., Willis J.,
RA   Dawson D., Willson J.K.V., Gazdar A.F., Hartigan J., Wu L., Liu C.,
RA   Parmigiani G., Park B.H., Bachman K.E., Papadopoulos N.,
RA   Vogelstein B., Kinzler K.W., Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal
RT   cancers.";
RL   Science 314:268-274(2006).
CC   -!- FUNCTION: DNA polymerase specifically involved in DNA repair.
CC       Plays an important role in translesion synthesis, where the normal
CC       high fidelity DNA polymerases cannot proceed and DNA synthesis
CC       stalls. Plays an important role in the repair of UV-induced
CC       pyrimidine dimers. Depending on the context, it inserts the
CC       correct base, but causes frequent base transitions and
CC       transversions. May play a role in hypermutation at immunoglobulin
CC       genes. Forms a Schiff base with 5'-deoxyribose phosphate at abasic
CC       sites, but does not have lyase activity. Targets POLI to
CC       replication foci. {ECO:0000269|PubMed:10385124,
CC       ECO:0000269|PubMed:11376341, ECO:0000269|PubMed:11743006,
CC       ECO:0000269|PubMed:14630940, ECO:0000269|PubMed:14734526}.
CC   -!- CATALYTIC ACTIVITY: Deoxynucleoside triphosphate + DNA(n) =
CC       diphosphate + DNA(n+1).
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC       Name=Mn(2+); Xref=ChEBI:CHEBI:29035;
CC       Note=Divalent metal cations. Prefers Mg(2+), but can also use
CC       Mn(2+).;
CC   -!- SUBUNIT: Interacts with REV1. Interacts with monoubiquitinated
CC       PCNA, but not unmodified PCNA. Interacts with POLI. Interacts with
CC       PALB2 and BRCA2; the interactions are direct and are involved in
CC       POLH localization at collapsed replication forks and DNA
CC       polymerization activity. {ECO:0000269|PubMed:12606586,
CC       ECO:0000269|PubMed:15149598, ECO:0000269|PubMed:24485656}.
CC   -!- INTERACTION:
CC       P51587:BRCA2; NbExp=6; IntAct=EBI-2827270, EBI-79792;
CC       Q86YC2:PALB2; NbExp=7; IntAct=EBI-2827270, EBI-1222653;
CC       Q6FI35:PCNA; NbExp=3; IntAct=EBI-2827270, EBI-8469539;
CC       P0CG48:UBC; NbExp=4; IntAct=EBI-2827270, EBI-3390054;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:12606586}.
CC       Note=Accumulates at replication forks after DNA damage.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q9Y253-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q9Y253-2; Sequence=VSP_012799;
CC         Note=No experimental confirmation available.;
CC   -!- DOMAIN: The catalytic core consists of fingers, palm and thumb
CC       subdomains, but the fingers and thumb subdomains are much smaller
CC       than in high-fidelity polymerases; residues from five sequence
CC       motifs of the Y-family cluster around an active site cleft that
CC       can accommodate DNA and nucleotide substrates with relaxed
CC       geometric constraints, with consequently higher rates of
CC       misincorporation and low processivity.
CC   -!- PTM: Monoubiquitinated by RCHY1/PIRH2; ubiquitination inhibits the
CC       ability of PolH to interact with PCNA and to bypass UV-induced
CC       lesions. {ECO:0000269|PubMed:20159558,
CC       ECO:0000269|PubMed:21791603}.
CC   -!- DISEASE: Xeroderma pigmentosum variant type (XPV) [MIM:278750]: An
CC       autosomal recessive pigmentary skin disorder characterized by
CC       solar hypersensitivity of the skin, high predisposition for
CC       developing cancers on areas exposed to sunlight and, in some
CC       cases, neurological abnormalities. XPV shows normal nucleotide
CC       excision repair, but an exaggerated delay in recovery of
CC       replicative DNA synthesis. Most patients with the variant type of
CC       xeroderma pigmentosum do not develop clinical symptoms and skin
CC       neoplasias until a later age. Clinical manifestations are limited
CC       to photo-induced deterioration of the skin and eyes.
CC       {ECO:0000269|PubMed:10385124, ECO:0000269|PubMed:10398605,
CC       ECO:0000269|PubMed:11032022, ECO:0000269|PubMed:11121129,
CC       ECO:0000269|PubMed:11773631, ECO:0000269|PubMed:24130121}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- SIMILARITY: Belongs to the DNA polymerase type-Y family.
CC       {ECO:0000305}.
CC   -!- SIMILARITY: Contains 1 umuC domain. {ECO:0000255|PROSITE-
CC       ProRule:PRU00216}.
CC   -!- WEB RESOURCE: Name=Allelic variations of the XP genes;
CC       URL="http://www.xpmutations.org/";
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/XPVID303.html";
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/polh/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AB024313; BAA81666.1; -; mRNA.
DR   EMBL; AF158185; AAD43810.1; -; mRNA.
DR   EMBL; AB038008; BAB18601.1; -; Genomic_DNA.
DR   EMBL; AY388614; AAQ81300.1; -; Genomic_DNA.
DR   EMBL; AL353602; CAI12786.1; -; Genomic_DNA.
DR   EMBL; AL355802; CAI12786.1; JOINED; Genomic_DNA.
DR   EMBL; AL353602; CAI12787.1; -; Genomic_DNA.
DR   EMBL; AL355802; CAI12787.1; JOINED; Genomic_DNA.
DR   EMBL; AL355802; CAI42641.1; -; Genomic_DNA.
DR   EMBL; AL353602; CAI42641.1; JOINED; Genomic_DNA.
DR   EMBL; AL355802; CAI42642.1; -; Genomic_DNA.
DR   EMBL; AL353602; CAI42642.1; JOINED; Genomic_DNA.
DR   EMBL; BC015742; AAH15742.1; -; mRNA.
DR   CCDS; CCDS4902.1; -. [Q9Y253-1]
DR   CCDS; CCDS78147.1; -. [Q9Y253-2]
DR   RefSeq; NP_001278899.1; NM_001291970.1. [Q9Y253-2]
DR   RefSeq; NP_006493.1; NM_006502.2. [Q9Y253-1]
DR   UniGene; Hs.655467; -.
DR   PDB; 2I5O; NMR; -; A=628-662.
DR   PDB; 2LSK; NMR; -; B=524-539.
DR   PDB; 3MR2; X-ray; 1.83 A; A=1-432.
DR   PDB; 3MR3; X-ray; 1.75 A; A=1-432.
DR   PDB; 3MR5; X-ray; 1.80 A; A=1-432.
DR   PDB; 3MR6; X-ray; 1.90 A; A=1-432.
DR   PDB; 3SI8; X-ray; 2.15 A; A=1-432.
DR   PDB; 3TQ1; X-ray; 2.56 A; A=1-432.
DR   PDB; 4DL2; X-ray; 2.15 A; A=1-432.
DR   PDB; 4DL3; X-ray; 2.10 A; A=1-432.
DR   PDB; 4DL4; X-ray; 2.00 A; A=1-432.
DR   PDB; 4DL5; X-ray; 2.92 A; A=1-432.
DR   PDB; 4DL6; X-ray; 2.50 A; A=1-432.
DR   PDB; 4DL7; X-ray; 1.97 A; A=1-432.
DR   PDB; 4ECQ; X-ray; 1.50 A; A=1-432.
DR   PDB; 4ECR; X-ray; 1.89 A; A=1-432.
DR   PDB; 4ECS; X-ray; 1.95 A; A=1-432.
DR   PDB; 4ECT; X-ray; 1.80 A; A=1-432.
DR   PDB; 4ECU; X-ray; 1.95 A; A=1-432.
DR   PDB; 4ECV; X-ray; 1.52 A; A=1-432.
DR   PDB; 4ECW; X-ray; 1.90 A; A=1-432.
DR   PDB; 4ECX; X-ray; 1.74 A; A=1-432.
DR   PDB; 4ECY; X-ray; 1.94 A; A=1-432.
DR   PDB; 4ECZ; X-ray; 1.83 A; A=1-432.
DR   PDB; 4ED0; X-ray; 1.65 A; A=1-432.
DR   PDB; 4ED1; X-ray; 1.81 A; A=1-432.
DR   PDB; 4ED2; X-ray; 1.71 A; A=1-432.
DR   PDB; 4ED3; X-ray; 1.79 A; A=1-432.
DR   PDB; 4ED6; X-ray; 2.21 A; A=1-432.
DR   PDB; 4ED7; X-ray; 1.72 A; A=1-432.
DR   PDB; 4ED8; X-ray; 1.52 A; A=1-432.
DR   PDB; 4EEY; X-ray; 2.32 A; A=1-432.
DR   PDB; 4J9K; X-ray; 2.03 A; A=1-432.
DR   PDB; 4J9L; X-ray; 1.85 A; A=1-432.
DR   PDB; 4J9M; X-ray; 2.25 A; A=1-432.
DR   PDB; 4J9N; X-ray; 1.96 A; A=1-432.
DR   PDB; 4J9O; X-ray; 2.60 A; A=1-432.
DR   PDB; 4J9P; X-ray; 2.30 A; A=1-432.
DR   PDB; 4J9Q; X-ray; 1.96 A; A=1-432.
DR   PDB; 4J9R; X-ray; 2.35 A; A=1-432.
DR   PDB; 4J9S; X-ray; 1.95 A; A=1-432.
DR   PDB; 4O3N; X-ray; 1.58 A; A=1-432.
DR   PDB; 4O3O; X-ray; 1.70 A; A=1-432.
DR   PDB; 4O3P; X-ray; 1.72 A; A=1-432.
DR   PDB; 4O3Q; X-ray; 1.72 A; A=1-432.
DR   PDB; 4O3R; X-ray; 1.62 A; A=1-432.
DR   PDB; 4O3S; X-ray; 1.72 A; A=1-432.
DR   PDB; 4Q8E; X-ray; 1.55 A; A=1-432.
DR   PDB; 4Q8F; X-ray; 2.80 A; A=1-432.
DR   PDB; 4RNM; X-ray; 2.14 A; A=1-432.
DR   PDB; 4RNN; X-ray; 1.81 A; A=1-432.
DR   PDB; 4RNO; X-ray; 2.82 A; A=1-432.
DR   PDB; 4YP3; X-ray; 1.89 A; A=1-432.
DR   PDB; 4YQW; X-ray; 2.06 A; A=1-432.
DR   PDB; 4YR0; X-ray; 1.78 A; A=1-432.
DR   PDB; 4YR2; X-ray; 1.95 A; A=1-432.
DR   PDB; 4YR3; X-ray; 2.00 A; A=1-432.
DR   PDBsum; 2I5O; -.
DR   PDBsum; 2LSK; -.
DR   PDBsum; 3MR2; -.
DR   PDBsum; 3MR3; -.
DR   PDBsum; 3MR5; -.
DR   PDBsum; 3MR6; -.
DR   PDBsum; 3SI8; -.
DR   PDBsum; 3TQ1; -.
DR   PDBsum; 4DL2; -.
DR   PDBsum; 4DL3; -.
DR   PDBsum; 4DL4; -.
DR   PDBsum; 4DL5; -.
DR   PDBsum; 4DL6; -.
DR   PDBsum; 4DL7; -.
DR   PDBsum; 4ECQ; -.
DR   PDBsum; 4ECR; -.
DR   PDBsum; 4ECS; -.
DR   PDBsum; 4ECT; -.
DR   PDBsum; 4ECU; -.
DR   PDBsum; 4ECV; -.
DR   PDBsum; 4ECW; -.
DR   PDBsum; 4ECX; -.
DR   PDBsum; 4ECY; -.
DR   PDBsum; 4ECZ; -.
DR   PDBsum; 4ED0; -.
DR   PDBsum; 4ED1; -.
DR   PDBsum; 4ED2; -.
DR   PDBsum; 4ED3; -.
DR   PDBsum; 4ED6; -.
DR   PDBsum; 4ED7; -.
DR   PDBsum; 4ED8; -.
DR   PDBsum; 4EEY; -.
DR   PDBsum; 4J9K; -.
DR   PDBsum; 4J9L; -.
DR   PDBsum; 4J9M; -.
DR   PDBsum; 4J9N; -.
DR   PDBsum; 4J9O; -.
DR   PDBsum; 4J9P; -.
DR   PDBsum; 4J9Q; -.
DR   PDBsum; 4J9R; -.
DR   PDBsum; 4J9S; -.
DR   PDBsum; 4O3N; -.
DR   PDBsum; 4O3O; -.
DR   PDBsum; 4O3P; -.
DR   PDBsum; 4O3Q; -.
DR   PDBsum; 4O3R; -.
DR   PDBsum; 4O3S; -.
DR   PDBsum; 4Q8E; -.
DR   PDBsum; 4Q8F; -.
DR   PDBsum; 4RNM; -.
DR   PDBsum; 4RNN; -.
DR   PDBsum; 4RNO; -.
DR   PDBsum; 4YP3; -.
DR   PDBsum; 4YQW; -.
DR   PDBsum; 4YR0; -.
DR   PDBsum; 4YR2; -.
DR   PDBsum; 4YR3; -.
DR   ProteinModelPortal; Q9Y253; -.
DR   SMR; Q9Y253; 1-432, 629-662.
DR   BioGrid; 111425; 23.
DR   IntAct; Q9Y253; 8.
DR   MINT; MINT-2789553; -.
DR   STRING; 9606.ENSP00000361310; -.
DR   BindingDB; Q9Y253; -.
DR   ChEMBL; CHEMBL5542; -.
DR   PhosphoSite; Q9Y253; -.
DR   BioMuta; POLH; -.
DR   DMDM; 59798441; -.
DR   MaxQB; Q9Y253; -.
DR   PaxDb; Q9Y253; -.
DR   PRIDE; Q9Y253; -.
DR   Ensembl; ENST00000372226; ENSP00000361300; ENSG00000170734. [Q9Y253-2]
DR   Ensembl; ENST00000372236; ENSP00000361310; ENSG00000170734.
DR   GeneID; 5429; -.
DR   UCSC; uc003ovq.4; human. [Q9Y253-1]
DR   CTD; 5429; -.
DR   GeneCards; GC06P043543; -.
DR   GeneReviews; POLH; -.
DR   HGNC; HGNC:9181; POLH.
DR   HPA; HPA006721; -.
DR   HPA; HPA026762; -.
DR   MIM; 278750; phenotype.
DR   MIM; 603968; gene.
DR   neXtProt; NX_Q9Y253; -.
DR   Orphanet; 90342; Xeroderma pigmentosum variant.
DR   PharmGKB; PA279; -.
DR   eggNOG; COG0389; -.
DR   GeneTree; ENSGT00530000062942; -.
DR   HOGENOM; HOG000115605; -.
DR   HOVERGEN; HBG053633; -.
DR   InParanoid; Q9Y253; -.
DR   OMA; RNKPCAV; -.
DR   PhylomeDB; Q9Y253; -.
DR   TreeFam; TF103010; -.
DR   BRENDA; 2.7.7.7; 2681.
DR   Reactome; REACT_1287; Translesion Synthesis by POLH.
DR   Reactome; REACT_355250; Termination of translesion DNA synthesis.
DR   SABIO-RK; Q9Y253; -.
DR   ChiTaRS; POLH; human.
DR   EvolutionaryTrace; Q9Y253; -.
DR   GeneWiki; DNA_polymerase_eta; -.
DR   GenomeRNAi; 5429; -.
DR   NextBio; 21005; -.
DR   PRO; PR:Q9Y253; -.
DR   Proteomes; UP000005640; Chromosome 6.
DR   Bgee; Q9Y253; -.
DR   CleanEx; HS_POLH; -.
DR   ExpressionAtlas; Q9Y253; baseline and differential.
DR   Genevisible; Q9Y253; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:HPA.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0003684; F:damaged DNA binding; TAS:ProtInc.
DR   GO; GO:0003887; F:DNA-directed DNA polymerase activity; TAS:ProtInc.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0071494; P:cellular response to UV-C; IEA:Ensembl.
DR   GO; GO:0006281; P:DNA repair; TAS:Reactome.
DR   GO; GO:0006260; P:DNA replication; IEA:UniProtKB-KW.
DR   GO; GO:0000731; P:DNA synthesis involved in DNA repair; IDA:UniProtKB.
DR   GO; GO:0070987; P:error-free translesion synthesis; TAS:Reactome.
DR   GO; GO:0006290; P:pyrimidine dimer repair; IEA:Ensembl.
DR   GO; GO:0006282; P:regulation of DNA repair; TAS:ProtInc.
DR   GO; GO:0010225; P:response to UV-C; IDA:UniProtKB.
DR   GO; GO:0019985; P:translesion synthesis; TAS:Reactome.
DR   Gene3D; 3.30.1490.100; -; 1.
DR   InterPro; IPR017061; DNA_pol_eta/kappa.
DR   InterPro; IPR017961; DNA_pol_Y-fam_little_finger.
DR   InterPro; IPR001126; DNA_repair_prot_UmuC-like.
DR   InterPro; IPR017963; DNA_repair_prot_UmuC-like_N.
DR   Pfam; PF00817; IMS; 1.
DR   Pfam; PF11799; IMS_C; 1.
DR   PIRSF; PIRSF036603; DPol_eta; 1.
DR   SUPFAM; SSF100879; SSF100879; 1.
DR   PROSITE; PS50173; UMUC; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Complete proteome;
KW   Direct protein sequencing; Disease mutation; DNA damage; DNA repair;
KW   DNA replication; DNA synthesis; DNA-binding;
KW   DNA-directed DNA polymerase; Isopeptide bond; Magnesium;
KW   Metal-binding; Mutator protein; Nucleotidyltransferase; Nucleus;
KW   Polymorphism; Reference proteome; Schiff base; Transferase;
KW   Ubl conjugation; Xeroderma pigmentosum.
FT   CHAIN         1    713       DNA polymerase eta.
FT                                /FTId=PRO_0000173986.
FT   DOMAIN        9    259       UmuC. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00216}.
FT   METAL        13     13       Magnesium. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00216}.
FT   METAL       115    115       Magnesium. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00216}.
FT   CROSSLNK    682    682       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin).
FT                                {ECO:0000269|PubMed:20159558}.
FT   CROSSLNK    686    686       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin).
FT                                {ECO:0000269|PubMed:20159558}.
FT   CROSSLNK    694    694       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin).
FT                                {ECO:0000269|PubMed:20159558}.
FT   CROSSLNK    709    709       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin).
FT                                {ECO:0000269|PubMed:20159558}.
FT   VAR_SEQ     415    713       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_012799.
FT   VARIANT      37     37       Missing (in XPV).
FT                                {ECO:0000269|PubMed:24130121}.
FT                                /FTId=VAR_070835.
FT   VARIANT      75     75       Missing (in XPV; impairs translesion
FT                                synthesis). {ECO:0000269|PubMed:10398605,
FT                                ECO:0000269|PubMed:11773631}.
FT                                /FTId=VAR_021226.
FT   VARIANT      93     93       R -> P (in XPV).
FT                                {ECO:0000269|PubMed:24130121}.
FT                                /FTId=VAR_070836.
FT   VARIANT     111    111       R -> H (in XPV).
FT                                /FTId=VAR_021227.
FT   VARIANT     122    122       T -> P (in XPV).
FT                                {ECO:0000269|PubMed:11773631}.
FT                                /FTId=VAR_021228.
FT   VARIANT     153    153       G -> D (in a breast cancer sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:16959974}.
FT                                /FTId=VAR_036220.
FT   VARIANT     209    209       G -> V (in dbSNP:rs2307456).
FT                                {ECO:0000269|Ref.4}.
FT                                /FTId=VAR_021229.
FT   VARIANT     263    263       G -> V (in XPV; impairs translesion
FT                                synthesis).
FT                                {ECO:0000269|PubMed:11773631}.
FT                                /FTId=VAR_021230.
FT   VARIANT     266    266       V -> D (in XPV).
FT                                {ECO:0000269|PubMed:24130121}.
FT                                /FTId=VAR_070837.
FT   VARIANT     295    295       G -> R (in XPV).
FT                                {ECO:0000269|PubMed:24130121}.
FT                                /FTId=VAR_070838.
FT   VARIANT     334    334       R -> W (in dbSNP:rs9333548).
FT                                {ECO:0000269|Ref.4}.
FT                                /FTId=VAR_021231.
FT   VARIANT     361    361       R -> S (in XPV).
FT                                {ECO:0000269|PubMed:11773631}.
FT                                /FTId=VAR_021232.
FT   VARIANT     478    478       T -> M (in dbSNP:rs9296419).
FT                                {ECO:0000269|Ref.4}.
FT                                /FTId=VAR_021233.
FT   VARIANT     535    535       K -> E (in XPV; dbSNP:rs56307355).
FT                                {ECO:0000269|PubMed:11121129}.
FT                                /FTId=VAR_021234.
FT   VARIANT     584    584       L -> P (in dbSNP:rs9333554).
FT                                {ECO:0000269|Ref.4}.
FT                                /FTId=VAR_021235.
FT   VARIANT     589    589       K -> T (in XPV).
FT                                {ECO:0000269|PubMed:11121129}.
FT                                /FTId=VAR_021236.
FT   VARIANT     595    595       M -> V (in dbSNP:rs9333555).
FT                                {ECO:0000269|Ref.4}.
FT                                /FTId=VAR_021237.
FT   VARIANT     647    647       M -> L (in dbSNP:rs6941583).
FT                                {ECO:0000269|Ref.4}.
FT                                /FTId=VAR_021238.
FT   VARIANT     692    692       T -> A (in XPV).
FT                                {ECO:0000269|PubMed:24130121}.
FT                                /FTId=VAR_070839.
FT   MUTAGEN      52     52       Y->A,F: Reduces DNA polymerase activity.
FT                                {ECO:0000269|PubMed:12644469}.
FT   MUTAGEN      52     52       Y->E: Reduces DNA polymerase activity.
FT                                Increases fidelity of replication and
FT                                reduces translesion bypass.
FT                                {ECO:0000269|PubMed:12644469}.
FT   HELIX         1      3       {ECO:0000244|PDB:3MR5}.
FT   STRAND        9     14       {ECO:0000244|PDB:4ECQ}.
FT   HELIX        17     25       {ECO:0000244|PDB:4ECQ}.
FT   HELIX        27     29       {ECO:0000244|PDB:4ECQ}.
FT   STRAND       34     38       {ECO:0000244|PDB:4ECQ}.
FT   TURN         41     44       {ECO:0000244|PDB:4ECQ}.
FT   STRAND       46     50       {ECO:0000244|PDB:4ECQ}.
FT   HELIX        52     55       {ECO:0000244|PDB:4ECQ}.
FT   TURN         56     58       {ECO:0000244|PDB:4ECQ}.
FT   STRAND       61     64       {ECO:0000244|PDB:4DL7}.
FT   HELIX        65     71       {ECO:0000244|PDB:4ECQ}.
FT   STRAND       76     79       {ECO:0000244|PDB:4ECQ}.
FT   STRAND       81     83       {ECO:0000244|PDB:4DL7}.
FT   STRAND       86     88       {ECO:0000244|PDB:4DL7}.
FT   HELIX        90    106       {ECO:0000244|PDB:4ECQ}.
FT   STRAND      109    113       {ECO:0000244|PDB:4ECQ}.
FT   STRAND      116    120       {ECO:0000244|PDB:4ECQ}.
FT   HELIX       122    132       {ECO:0000244|PDB:4ECQ}.
FT   HELIX       139    141       {ECO:0000244|PDB:4ECQ}.
FT   STRAND      145    147       {ECO:0000244|PDB:4ECQ}.
FT   HELIX       159    161       {ECO:0000244|PDB:3MR2}.
FT   HELIX       163    177       {ECO:0000244|PDB:4ECQ}.
FT   HELIX       186    208       {ECO:0000244|PDB:4ECQ}.
FT   STRAND      212    219       {ECO:0000244|PDB:4ECQ}.
FT   HELIX       220    229       {ECO:0000244|PDB:4ECQ}.
FT   TURN        230    233       {ECO:0000244|PDB:4J9O}.
FT   STRAND      235    237       {ECO:0000244|PDB:4ECQ}.
FT   HELIX       240    242       {ECO:0000244|PDB:4ECQ}.
FT   HELIX       243    248       {ECO:0000244|PDB:4ECQ}.
FT   HELIX       252    254       {ECO:0000244|PDB:4ECQ}.
FT   TURN        256    259       {ECO:0000244|PDB:4RNO}.
FT   HELIX       261    270       {ECO:0000244|PDB:4ECQ}.
FT   HELIX       275    280       {ECO:0000244|PDB:4ECQ}.
FT   HELIX       283    290       {ECO:0000244|PDB:4ECQ}.
FT   HELIX       292    301       {ECO:0000244|PDB:4ECQ}.
FT   TURN        302    304       {ECO:0000244|PDB:4ECQ}.
FT   STRAND      313    315       {ECO:0000244|PDB:3TQ1}.
FT   STRAND      319    324       {ECO:0000244|PDB:4ECQ}.
FT   HELIX       327    329       {ECO:0000244|PDB:4ECQ}.
FT   STRAND      331    333       {ECO:0000244|PDB:4ECQ}.
FT   HELIX       334    359       {ECO:0000244|PDB:4ECQ}.
FT   STRAND      360    372       {ECO:0000244|PDB:4ECQ}.
FT   TURN        373    375       {ECO:0000244|PDB:4YQW}.
FT   STRAND      376    378       {ECO:0000244|PDB:4O3R}.
FT   STRAND      380    386       {ECO:0000244|PDB:4ECQ}.
FT   HELIX       392    403       {ECO:0000244|PDB:4ECQ}.
FT   HELIX       404    406       {ECO:0000244|PDB:4ECQ}.
FT   STRAND      414    431       {ECO:0000244|PDB:4ECQ}.
FT   HELIX       532    538       {ECO:0000244|PDB:2LSK}.
FT   STRAND      632    634       {ECO:0000244|PDB:2I5O}.
FT   TURN        636    638       {ECO:0000244|PDB:2I5O}.
FT   STRAND      641    643       {ECO:0000244|PDB:2I5O}.
FT   HELIX       644    646       {ECO:0000244|PDB:2I5O}.
FT   HELIX       647    659       {ECO:0000244|PDB:2I5O}.
SQ   SEQUENCE   713 AA;  78413 MW;  6D1D35A0F56ECE89 CRC64;
     MATGQDRVVA LVDMDCFFVQ VEQRQNPHLR NKPCAVVQYK SWKGGGIIAV SYEARAFGVT
     RSMWADDAKK LCPDLLLAQV RESRGKANLT KYREASVEVM EIMSRFAVIE RASIDEAYVD
     LTSAVQERLQ KLQGQPISAD LLPSTYIEGL PQGPTTAEET VQKEGMRKQG LFQWLDSLQI
     DNLTSPDLQL TVGAVIVEEM RAAIERETGF QCSAGISHNK VLAKLACGLN KPNRQTLVSH
     GSVPQLFSQM PIRKIRSLGG KLGASVIEIL GIEYMGELTQ FTESQLQSHF GEKNGSWLYA
     MCRGIEHDPV KPRQLPKTIG CSKNFPGKTA LATREQVQWW LLQLAQELEE RLTKDRNDND
     RVATQLVVSI RVQGDKRLSS LRRCCALTRY DAHKMSHDAF TVIKNCNTSG IQTEWSPPLT
     MLFLCATKFS ASAPSSSTDI TSFLSSDPSS LPKVPVTSSE AKTQGSGPAV TATKKATTSL
     ESFFQKAAER QKVKEASLSS LTAPTQAPMS NSPSKPSLPF QTSQSTGTEP FFKQKSLLLK
     QKQLNNSSVS SPQQNPWSNC KALPNSLPTE YPGCVPVCEG VSKLEESSKA TPAEMDLAHN
     SQSMHASSAS KSVLEVTQKA TPNPSLLAAE DQVPCEKCGS LVPVWDMPEH MDYHFALELQ
     KSFLQPHSSN PQVVSAVSHQ GKRNPKSPLA CTNKRPRPEG MQTLESFFKP LTH
//
